-
Lumasiran, sold
under the
brand name Oxlumo, is a
medication for the
treatment of
primary hyperoxaluria type 1 (PH1). The most
common side
effects include...
-
authorities in the US and Europe:
patisiran (2018),
givosiran (2019),
lumasiran (2020),
inclisiran (2020 in
Europe with anti****ted US
approval in 2021)...
- as the main
source of
oxalate is
endogenous in
primary hyperoxaluria.
Lumasiran, an RNA
interference therapeutic drug, is
indicated for the treatment...
-
Migalastat A16AX15
Telotristat A16AX16
Givosiran A16AX17
Triheptanoin A16AX18
Lumasiran A16AX19
Fosdenopterin A16AX20
Lonafarnib A16AX21
Elivaldogene autotemcel...
- GIVLAARI, were
available for
commercial application, and two siRNAs,
lumasiran (ALN-GO1) and inclisiran, have been
submitted for new drug application...
- processing-deficient
progeroid laminopathies with LMNA or ZMPSTE24
mutations Lumasiran Alnylam Pharmaceuticals primary hyperoxaluria type 1 Naxitamab-gqgk Y-mAbs...
-
efficiency of the
delivery of
naked mRNA in vivo.
patisiran givosiran lumasiran inclisiran Antisense RNA is the non-coding and single-stranded RNA that...
